Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

ITP (immune thrombocytopenia) is an autoimmune disorder where the body attacks its own blood platelets. This leads to a decrease in the number of platelets and consequently can cause a number of ...

The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...

ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life ...

Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard ...

SAN DIEGO -- Treatment with eltrombopag (Promacta) for pediatric patients with newly diagnosed immune thrombocytopenia (ITP) led to a significantly higher rate of durable platelet response compared ...

Adding ianalumab to standard-of-care second-line eltrombopag prolonged the time to treatment failure vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) in the pivotal ...

Sanofi’s Wayrilz, the first BTK inhibitor to treat immune thrombocytopenia gets European approval: Paris Saturday, December 27, 2025, 12:00 Hrs [IST] Sanofi, an R&D driven, AI-p ...

Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by both antibody-mediated platelet destruction and impaired megakaryocyte function. This results in decreased platelet counts and ...

Noncancerous blood disorders are conditions that affect blood cells, such as red blood cells, white blood cells, and platelets. Blood disorders may cause symptoms and complications, but most are ...